Eli Lilly has followed Novo Nordisk in announcing a big investment in its manufacturing network, intended to meet anticipated strong future demand for diabetes and obesity drugs. The pharma group ...

Unlike Lilly’s injectable GLP-1 currently on ... of its GLP-1 semaglutide as Rybelsus, though the drug is only approved in type 2 diabetes. Meanwhile, Evercore ISI analyst Umer Raffat said ...

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Weight loss injectables like Ozempic have gained popularity in Bengaluru, with patients sourcing them from abroad. The ...

Eli Lilly will spend $3 billion ... in Wisconsin to provide capacity for injectable products, including its fast-growing obesity and diabetes drugs. Lilly bought the plant in Pleasant Prairie ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the popular diabetes ... The injectable drugs have been in shortage since 2022.

Eli Lilly wants the most optimal locations to host its new manufacturing facilities in the U.S.—and it’s open to pitche | Eli ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...